Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment
about
A Longitudinal Study of Predictors of Sexual Dysfunction in Men on Active Surveillance for Prostate CancerChanges in Nocturia and Lower Urinary Tract Symptoms after Radical Prostatectomy.Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.Cancer Related Fatigue and Quality of Life in Patients with Advanced Prostate Cancer Undergoing Chemotherapy.Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment.'Killing two birds with one stone': patient-reported quality-of-life outcomes from the Prostate Testing for Cancer and Treatment (ProtecT) trial.Influence of radical prostatectomy for prostate cancer on work status and working life 3 years after surgery.Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer.
P2860
Q36142085-212C622C-E0DF-42BF-AE73-BE984830FD9FQ36452989-8A9BD4C2-EF46-494C-8656-AA801C1EBCE2Q37175207-A7A327B2-1C4C-4037-AA0E-3052F7F6A2E1Q37420446-BC3144DD-B551-420D-BFAD-F7F59DCEA095Q38792110-CFB9416D-0F1E-4C0A-BB01-C67E740FCCBEQ38890085-5ECAE42C-89AB-4C18-A1E4-FD0B26E1D10EQ39917062-32D9CE18-2911-462E-9ABC-7DC3F50FEF43Q45362552-5D050537-6DAE-4E19-97B1-0814B392FDC3Q48030324-29458F1E-9F30-48EC-A065-E132614D3BA0Q48065569-E3CB5026-B512-4916-B26A-DF1F7724710AQ49834246-2C5BC9DE-E55D-4A25-9014-EDBA5A6B0E74
P2860
Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Contemporary prevalence of pre ...... s of prostate cancer treatment
@en
Contemporary prevalence of pre ...... of prostate cancer treatment.
@nl
type
label
Contemporary prevalence of pre ...... s of prostate cancer treatment
@en
Contemporary prevalence of pre ...... of prostate cancer treatment.
@nl
prefLabel
Contemporary prevalence of pre ...... s of prostate cancer treatment
@en
Contemporary prevalence of pre ...... of prostate cancer treatment.
@nl
P2093
P2860
P50
P356
P1433
P1476
Contemporary prevalence of pre ...... s of prostate cancer treatment
@en
P2093
Alicia K Morgans
Ann S Hamilton
Antoinette M Stroup
Daniel A Barocas
Karen E Hoffman
Lisa E Paddock
Matthew J Resnick
Michael Goodman
Sharon E Phillips
Sherri H Kaplan
P2860
P304
P356
10.1002/CNCR.28563
P407
P577
2014-02-07T00:00:00Z